Furthermore, IFNβ triggers soluble TRAIL (sTRAIL) secretion; serum levels of sTRAIL increased in NPC patients under IFNβ maintenance therapy [130]. The gene discussed is IFNB1; the disease is nasopharyngeal carcinoma.